

Rapid clinical application of specific inhibitors targeting refractory gastrointestinal cancer stem cells

Principal Investigator

Department of Medical Data Science, Graduate School of Medicine,
The University of Osaka

Professor Hideshi ISHII


Project Outline

A Novel DDS loaded with Ubenimex, a Specific CD13 Inhibitor, to Target Refractory Gastrointestinal Cancer Stem Cells


Background

- We reported CD13 as a marker of cancer stem cells (CSCs) in patients with hepatocellular carcinoma (HCC). (*J Clin Invest* 2010)
- As a specific CD13 inhibitor, Ubenimex has been used as a maintenance therapy for adult acute non-lymphatic leukemia (ANLL) in Japan.
- The effective dose of Ubenimex for HCC needs to be much higher than the currently used dose for ANLL.

We developed a novel drug delivery system (DDS) loaded with Ubenimex to enhance its efficacy for CSCs in HCC.



The anti-cancer effect of Ubenimex was enhanced.



DDSX-Ubenimex suppressed tumor growth.

Reference

- Patents
 - Japan: 2018-013678
 - Global: Applying
- Journals
 - *J Clin Invest* 2010;120(9):3326–3339.
 - *Oncogene* 2019;38(2):244-260.

Business Opportunity

- Collaboration
 - Nonclinical safety experiments (monkey etc.)
 - Manufacturing (GLP, GMP grade)
- Funding
 - Clinical development

Contact to: TEL : 06-6210-8406 / FAX : 06-6210-8407 E-mail : hishii@gesurg.med.osaka-u.ac.jp

Works are underway with regard to: target disease, patent information, technical features, marketability, development challenges, business opportunity sought (joint development, licensing-out, etc.), information to clarify the division of roles between companies and academia.